• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Adderall XR

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Adderall XR

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Adderall XR, an extended release formulation of Shire's previously approved ADHD treatment Adderall, has been approved for treatment of ADHD in children. This once-daily capsule provides all day treatment with one morning dose, unlike most ADHD treatments that require a midday dose. This dosing regimen eliminates the social stigma issues felt by children having to bring medication to school and decreases the possibility of medication misuse.

    ADHD is the most commonly diagnosed psychiatric disorder among school-aged children. Symptoms include inattentive, impulsive and hyperactive behavior that interferes with a child's ability to properly function in academic and social settings.

    Clinical Results

    Approval of Adderall XR is based on two clinical studies, involving more than 600 pediatric subjects at over 50 sites. Results from a laboratory classroom study showed that Adderall XR provided longer-lasting symptom control than the original Adderall. Adderall XR demonstrated statistically significant superiority in symptom control over placebo at all times observed from 1.5 to 12 hours after dosing. Symptoms included hyperactivity, impulsivity and the inability to work, focus and learn.

    In a second clinical study, including more than 500 ADHD diagnosed children, a morning administration of Adderall XR was shown to provide as significant an improvement in attention and behavior at 4 p.m. as was observed at 10 a.m.

    Side Effects

    Adverse events associated with the use of Adderall XR may include (but are not limited to) the following:


    • Anorexia
    • Insomnia
    • Abdominal pain
    • Emotional lability
    • Nervousness

    Mechanism of Action

    Adderall XR is an amphetamine product that acts as a stimulant to the central nervous system. It is unknown through which mechanism amphetamines produce mental and behavioral effects in children.

    Additional Information

    For additional information on attention deficit/hyperactivity disorder, please visit ADHD.com.

    Approval Date: 2001-10-01
    Company Name: Shire Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 16Oct

      MAGI@home Clinical Research Conference 2023

    • 25Oct

      2023 WCG Patient Forum

    • 26Oct

      FDA in 2024: What to Expect in an Election Year

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Donna Snyder

      New WCG Executive Physician Outlines Goals for Clinical Research

    • Hand Shake at Meeting

      Partnership to Bolster Trials in Low Resource Regions Kicks Off

    • Guidelines-360x240.png

      Major Industry Groups Offer Feedback on ICH’s E6(R3) Guidelines

    • AsktheExpertsBadge-360x240.png

      Ask the Experts: Monitoring

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing